ArticleScientific reports2018

Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.

Shuchun Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.